664 results on '"Sadelain, Michel"'
Search Results
2. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
3. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
4. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
5. Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
6. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy
7. HLA-independent T cell receptors for targeting tumors with low antigen density.
8. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
9. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
10. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
11. Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies
12. TET2 guards against unchecked BATF3-induced CAR T cell expansion
13. Cooperative CAR targeting to selectively eliminate AML and minimize escape
14. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
15. CAR T cell design: approaching the elusive AND-gate
16. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
17. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering
18. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
19. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
20. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
21. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.
22. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
23. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
24. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
25. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial
26. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
27. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy
28. CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
29. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.
30. Figure S7 from Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function
31. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function
32. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
33. Senolytic CAR T cells reverse senescence-associated pathologies
34. Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies
35. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
36. 512 Targeting HLA-E positive cancers with a novel NKG2A/C switch receptor
37. Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells
38. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
39. Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology
40. S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
41. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
42. Gene therapy comes of age
43. CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials
44. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia
45. Posttransplant chimeric antigen receptor therapy
46. Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
47. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
48. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
49. Table 1 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
50. Figure 2 from Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.